Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount
Menarini Remains In Front
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.
You may also be interested in...
With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.
Sanofi can now expect an FDA decision in early 2023 on efanesoctocog, setting it up for a battle with Roche’s Hemlibra and BioMarin’s gene therapy Roctavian, which was just approved in the EU.
Roche's giredestrant failed to show a benefit on progression-free survival in the Phase II acelERA trial in people with advanced breast cancer.